Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy (PE-POD)
Primary Purpose
Delirium, Cognitive Impairment, Post-traumatic Stress Disorder
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Haloperidol
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Delirium focused on measuring delirium, confusion, surgery, cognitive Impairment, post-traumatic Stress disorder, depression, anxiety
Eligibility Criteria
Inclusion Criteria:
- At least ≥ 18 years of age and older
- Undergoing a possible or scheduled thoracotomy
- English speaking
Exclusion Criteria:
- History of Schizophrenia and Parkinson's disease
- History of Severe Dementia
- History of Alcohol Abuse
- On Cholinesterase Inhibitors or Levodopa
- Pregnant or Nursing
- Corrected QT interval > 550 milliseconds at the time of randomization
- History of Neuroleptic Malignant Syndrome or Haloperidol Allergy
Sites / Locations
- University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Haloperidol
Placebo
Arm Description
Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
Outcomes
Primary Outcome Measures
Efficacy of Low-dose Haloperidol in Reducing Delirium Incidence
Test the efficacy of low dose haloperidol in reducing delirium incidence among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo.
Secondary Outcome Measures
Efficacy of Low-dose Haloperidol in Reducing Days With Delirium
Test the efficacy of low dose haloperidol in reducing the number of days with delirium among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo.
Efficacy of Low-dose Haloperidol in Reducing ICU and Hospital Length of Stay
Test the efficacy of low dose haloperidol in reducing ICU and hospital length of stay among patients who are status post esophagectomy or pneumonectomy compared to placebo.
Efficacy of Low-dose Haloperidol in Reducing Cognitive Impairment at Post-operative Follow-up
Test the efficacy of low dose haloperidol in reducing cognitive impairment at post-operative follow-up among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. Cognitive status is assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The RBANS measures attention, language, visuospatial/constructional abilities, and memory. It is made up of 12 subtests. The subtests produce 5 index scores and a total scale score. All the subtest scores are summed to calculate a Total Index score. The Total Index score is presented. The Total Index score scale is from 0-100 with higher scores indicating less cognitive impairment.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02213900
Brief Title
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
Acronym
PE-POD
Official Title
Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to investigate the effectiveness of a preventative low-dose of Haloperidol to prevent delirium in patients undergoing a esophagectomy, pneumonectomy or thoracotomy.
Delirium is state of severe confusion and some symptoms include:
Cannot think clearly
Have trouble paying attention
Have a hard time understanding what is going on around them
May see or hear things that are not there. These things seem very real to them.
Detailed Description
50% of patients who undergo esophageal and/or lung resection suffer from acute brain dysfunction or delirium postoperatively. Delirium is a state of brain failure characterized by disturbance of consciousness with reduced ability to focus, sustain, or shift attention that occurs over a short period of time and tends to fluctuate over the course of the day. Presence of delirium in the post-operative phase is associated with a longer length of both intensive care unit and hospital stay, increased health-care costs, long-term functional and cognitive decline, and an increased risk of in-hospital and post-discharge mortality.
Haloperidol primarily acts by blocking dopamine (D2) receptors. This dopamine blockade in the cerebral cortex improves cognition and reduces delirium. Along with the dopamine blockade, haloperidol has anti-inflammatory properties. It inhibits production of lipopolysaccharide induced pro-inflammatory cytokines, interleukin (IL-1) and tumor necrosis factor alpha (TNF-α). Haloperidol also increases levels of Interleukin -1 receptor antagonist (IL-1RA), an anti-inflammatory cytokine that blocks the action of other pro-inflammatory cytokines. If unchecked, the inflammatory cytokines cause impaired concentration, sleep disturbances, and agitation the cardinal symptoms of delirium; and induce a reduction in cholinergic activity. Given the inhibitory effect of acetylcholine on certain cytokines such as interleukin-6, a repetitive cycle of inadequate regulation of inflammation due to cholinergic depletion ensues. Haloperidol with its anti-inflammatory properties seeks to mitigate this repetitive vicious cycle.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium, Cognitive Impairment, Post-traumatic Stress Disorder, Depression, Anxiety
Keywords
delirium, confusion, surgery, cognitive Impairment, post-traumatic Stress disorder, depression, anxiety
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
135 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Haloperidol
Arm Type
Experimental
Arm Description
Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
Intervention Type
Drug
Intervention Name(s)
Haloperidol
Intervention Description
0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Efficacy of Low-dose Haloperidol in Reducing Delirium Incidence
Description
Test the efficacy of low dose haloperidol in reducing delirium incidence among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo.
Time Frame
Up to 30 days
Secondary Outcome Measure Information:
Title
Efficacy of Low-dose Haloperidol in Reducing Days With Delirium
Description
Test the efficacy of low dose haloperidol in reducing the number of days with delirium among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo.
Time Frame
Up to 30 days
Title
Efficacy of Low-dose Haloperidol in Reducing ICU and Hospital Length of Stay
Description
Test the efficacy of low dose haloperidol in reducing ICU and hospital length of stay among patients who are status post esophagectomy or pneumonectomy compared to placebo.
Time Frame
Date of hospital admission through date of hospital discharge, up to 3 weeks on average.
Title
Efficacy of Low-dose Haloperidol in Reducing Cognitive Impairment at Post-operative Follow-up
Description
Test the efficacy of low dose haloperidol in reducing cognitive impairment at post-operative follow-up among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. Cognitive status is assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The RBANS measures attention, language, visuospatial/constructional abilities, and memory. It is made up of 12 subtests. The subtests produce 5 index scores and a total scale score. All the subtest scores are summed to calculate a Total Index score. The Total Index score is presented. The Total Index score scale is from 0-100 with higher scores indicating less cognitive impairment.
Time Frame
Up to 3 months after hospital discharge on average.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
At least ≥ 18 years of age and older
Undergoing a possible or scheduled thoracotomy
English speaking
Exclusion Criteria:
History of Schizophrenia and Parkinson's disease
History of Severe Dementia
History of Alcohol Abuse
On Cholinesterase Inhibitors or Levodopa
Pregnant or Nursing
Corrected QT interval > 550 milliseconds at the time of randomization
History of Neuroleptic Malignant Syndrome or Haloperidol Allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Babar A Khan, MD, MS
Organizational Affiliation
Regenstrief Institute, Inc.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kenneth A Kesler, MD
Organizational Affiliation
IU School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
30460981
Citation
Khan BA, Perkins AJ, Campbell NL, Gao S, Khan SH, Wang S, Fuchita M, Weber DJ, Zarzaur BL, Boustani MA, Kesler K. Preventing Postoperative Delirium After Major Noncardiac Thoracic Surgery-A Randomized Clinical Trial. J Am Geriatr Soc. 2018 Dec;66(12):2289-2297. doi: 10.1111/jgs.15640. Epub 2018 Nov 21.
Results Reference
derived
Learn more about this trial
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
We'll reach out to this number within 24 hrs